{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:25:18Z","timestamp":1791897918993,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015160","name":"Hologic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s10549-023-06865-8","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T12:52:27Z","timestamp":1675947147000},"page":"349-359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Contrast-enhanced mammography in the assessment of residual disease after neoadjuvant treatment"],"prefix":"10.1007","volume":"198","author":[{"given":"Molly P.","family":"Hogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5699-2094","authenticated-orcid":false,"given":"Joao V.","family":"Horvat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varadan","family":"Sevilimedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine S.","family":"Jochelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie J.","family":"Kirstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari B.","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Comstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice S.","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"6865_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123495","author":"J Gluskin","year":"2020","unstructured":"Gluskin J, Rossi Saccarelli C, Avendano D, Marino MA, Bitencourt AGV, Pilewskie M et al (2020) Contrast-enhanced mammography for screening women after breast conserving surgery. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12123495","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6865_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1148\/radiol.2019182660","volume":"293","author":"JS Sung","year":"2019","unstructured":"Sung JS, Lebron L, Keating D, D\u2019Alessio D, Comstock CE, Lee CH et al (2019) Performance of dual-energy contrast-enhanced digital mammography for screening women at increased risk of breast cancer. Radiology 293(1):81\u201388. https:\/\/doi.org\/10.1148\/radiol.2019182660","journal-title":"Radiology"},{"issue":"3","key":"6865_CR3","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1148\/radiol.211412","volume":"302","author":"A Cozzi","year":"2022","unstructured":"Cozzi A, Magni V, Zanardo M, Schiaffino S, Sardanelli F (2022) Contrast-enhanced mammography: a systematic review and meta-analysis of diagnostic performance. Radiology 302(3):568\u2013581. https:\/\/doi.org\/10.1148\/radiol.211412","journal-title":"Radiology"},{"issue":"7","key":"6865_CR4","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1007\/s00330-016-4650-6","volume":"27","author":"EM Fallenberg","year":"2017","unstructured":"Fallenberg EM, Schmitzberger FF, Amer H, Ingold-Heppner B, Balleyguier C, Diekmann F et al (2017) Contrast-enhanced spectral mammography vs. mammography and MRI - clinical performance in a multi-reader evaluation. Eur Radiol 27(7):2752\u20132764. https:\/\/doi.org\/10.1007\/s00330-016-4650-6","journal-title":"Eur Radiol"},{"issue":"3","key":"6865_CR5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1148\/radiol.12121084","volume":"266","author":"MS Jochelson","year":"2013","unstructured":"Jochelson MS, Dershaw DD, Sung JS, Heerdt AS, Thornton C, Moskowitz CS et al (2013) Bilateral contrast-enhanced dual-energy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma. Radiology 266(3):743\u2013751. https:\/\/doi.org\/10.1148\/radiol.12121084","journal-title":"Radiology"},{"issue":"1118","key":"6865_CR6","doi-asserted-by":"publisher","first-page":"20201046","DOI":"10.1259\/bjr.20201046","volume":"94","author":"R Sudhir","year":"2021","unstructured":"Sudhir R, Sannapareddy K, Potlapalli A, Krishnamurthy PB, Buddha S, Koppula V (2021) Diagnostic accuracy of contrast-enhanced digital mammography in breast cancer detection in comparison to tomosynthesis, synthetic 2D mammography and tomosynthesis combined with ultrasound in women with dense breast. Br J Radiol 94(1118):20201046. https:\/\/doi.org\/10.1259\/bjr.20201046","journal-title":"Br J Radiol"},{"issue":"8","key":"6865_CR7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.ejrad.2014.05.015","volume":"83","author":"MA Francescone","year":"2014","unstructured":"Francescone MA, Jochelson MS, Dershaw DD, Sung JS, Hughes MC, Zheng J et al (2014) Low energy mammogram obtained in contrast-enhanced digital mammography (CEDM) is comparable to routine full-field digital mammography (FFDM). Eur J Radiol 83(8):1350\u20131355. https:\/\/doi.org\/10.1016\/j.ejrad.2014.05.015","journal-title":"Eur J Radiol"},{"issue":"1","key":"6865_CR8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00330-013-3007-7","volume":"24","author":"EM Fallenberg","year":"2014","unstructured":"Fallenberg EM, Dromain C, Diekmann F, Engelken F, Krohn M, Singh JM et al (2014) Contrast-enhanced spectral mammography versus MRI: initial results in the detection of breast cancer and assessment of tumour size. Eur Radiol 24(1):256\u2013264. https:\/\/doi.org\/10.1007\/s00330-013-3007-7","journal-title":"Eur Radiol"},{"issue":"3","key":"6865_CR9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1148\/radiol.2019190887","volume":"293","author":"JH Sumkin","year":"2019","unstructured":"Sumkin JH, Berg WA, Carter GJ, Bandos AI, Chough DM, Ganott MA et al (2019) Diagnostic performance of mri, molecular breast imaging, and contrast-enhanced mammography in women with newly diagnosed breast cancer. Radiology 293(3):531\u2013540. https:\/\/doi.org\/10.1148\/radiol.2019190887","journal-title":"Radiology"},{"issue":"2","key":"6865_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1148\/radiol.2017161592","volume":"285","author":"SA Lee-Felker","year":"2017","unstructured":"Lee-Felker SA, Tekchandani L, Thomas M, Gupta E, Andrews-Tang D, Roth A et al (2017) Newly diagnosed breast cancer: comparison of contrast-enhanced spectral mammography and breast mr imaging in the evaluation of extent of disease. Radiology 285(2):389\u2013400. https:\/\/doi.org\/10.1148\/radiol.2017161592","journal-title":"Radiology"},{"issue":"13","key":"6865_CR11","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES et al (2021) Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 39(13):1485\u20131505. https:\/\/doi.org\/10.1200\/JCO.20.03399","journal-title":"J Clin Oncol"},{"issue":"4","key":"6865_CR12","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1245\/s10434-020-09480-9","volume":"28","author":"RA Leon-Ferre","year":"2021","unstructured":"Leon-Ferre RA, Hieken TJ, Boughey JC (2021) The landmark series: neoadjuvant chemotherapy for triple-negative and HER2-Positive breast cancer. Ann Surg Oncol 28(4):2111\u20132119. https:\/\/doi.org\/10.1245\/s10434-020-09480-9","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"6865_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1245\/s10434-018-07107-8","volume":"26","author":"AM Pease","year":"2019","unstructured":"Pease AM, Riba LA, Gruner RA, Tung NM, James TA (2019) Oncotype DX((R)) recurrence score as a predictor of response to neoadjuvant chemotherapy. Ann Surg Oncol 26(2):366\u2013371. https:\/\/doi.org\/10.1245\/s10434-018-07107-8","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"6865_CR14","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1245\/s10434-015-4406-6","volume":"22","author":"EP Mamounas","year":"2015","unstructured":"Mamounas EP (2015) Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer. Ann Surg Oncol 22(5):1425\u20131433. https:\/\/doi.org\/10.1245\/s10434-015-4406-6","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"6865_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","volume":"19","author":"EBCTCG","year":"2018","unstructured":"EBCTCG (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 19(1):27\u201339. https:\/\/doi.org\/10.1016\/S1470-2045(17)30777-5","journal-title":"Lancet Oncol"},{"issue":"12","key":"6865_CR16","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL et al (2020) Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res 26(12):2838\u20132848. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3492","journal-title":"Clin Cancer Res"},{"issue":"5","key":"6865_CR17","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1245\/s10434-015-4502-7","volume":"22","author":"MS Jochelson","year":"2015","unstructured":"Jochelson MS, Lampen-Sachar K, Gibbons G, Dang C, Lake D, Morris EA et al (2015) Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy? Ann Surg Oncol 22(5):1490\u20131495. https:\/\/doi.org\/10.1245\/s10434-015-4502-7","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"6865_CR18","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1245\/s10434-016-5741-y","volume":"24","author":"Y Feliciano","year":"2017","unstructured":"Feliciano Y, Mamtani A, Morrow M, Stempel MM, Patil S, Jochelson MS (2017) Do Calcifications seen on mammography after neoadjuvant chemotherapy for breast cancer always need to be excised? Ann Surg Oncol 24(6):1492\u20131498. https:\/\/doi.org\/10.1245\/s10434-016-5741-y","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"6865_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/jnci\/djs528","volume":"105","author":"ML Marinovich","year":"2013","unstructured":"Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP et al (2013) Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst 105(5):321\u2013333. https:\/\/doi.org\/10.1093\/jnci\/djs528","journal-title":"J Natl Cancer Inst"},{"key":"6865_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clinimag.2017.07.001","volume":"46","author":"BK Patel","year":"2017","unstructured":"Patel BK, Garza SA, Eversman S, Lopez-Alvarez Y, Kosiorek H, Pockaj BA (2017) Assessing tumor extent on contrast-enhanced spectral mammography versus full-field digital mammography and ultrasound. Clin Imaging 46:78\u201384. https:\/\/doi.org\/10.1016\/j.clinimag.2017.07.001","journal-title":"Clin Imaging"},{"issue":"7","key":"6865_CR21","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/tbj.13766","volume":"26","author":"G Bicchierai","year":"2020","unstructured":"Bicchierai G, Tonelli P, Piacenti A, De Benedetto D, Boeri C, Vanzi E et al (2020) Evaluation of contrast-enhanced digital mammography (CEDM) in the preoperative staging of breast cancer: large-scale single-center experience. Breast J 26(7):1276\u20131283. https:\/\/doi.org\/10.1111\/tbj.13766","journal-title":"Breast J"},{"key":"6865_CR22","doi-asserted-by":"publisher","first-page":"8531916","DOI":"10.1155\/2018\/8531916","volume":"2018","author":"FR Barra","year":"2018","unstructured":"Barra FR, Sobrinho AB, Barra RR, Magalh\u00e3es MT, Aguiar LR, de Albuquerque GFL et al (2018) Contrast-enhanced mammography (CEM) for detecting residual disease after neoadjuvant chemotherapy: a comparison with breast magnetic resonance imaging (MRI). Biomed Res Int 2018:8531916. https:\/\/doi.org\/10.1155\/2018\/8531916","journal-title":"Biomed Res Int"},{"issue":"1","key":"6865_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13058-017-0899-1","volume":"19","author":"V Iotti","year":"2017","unstructured":"Iotti V, Ravaioli S, Vacondio R, Coriani C, Caffarri S, Sghedoni R et al (2017) Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging. Breast Cancer Res 19(1):106. https:\/\/doi.org\/10.1186\/s13058-017-0899-1","journal-title":"Breast Cancer Res"},{"issue":"5","key":"6865_CR24","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1245\/s10434-018-6413-x","volume":"25","author":"BK Patel","year":"2018","unstructured":"Patel BK, Hilal T, Covington M, Zhang N, Kosiorek HE, Lobbes M et al (2018) Contrast-Enhanced spectral mammography is comparable to MRI in the assessment of residual breast cancer following neoadjuvant systemic therapy. Ann Surg Oncol 25(5):1350\u20131356. https:\/\/doi.org\/10.1245\/s10434-018-6413-x","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"6865_CR25","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s00330-002-1730-6","volume":"13","author":"K Wasser","year":"2003","unstructured":"Wasser K, Sinn HP, Fink C, Klein SK, Junkermann H, L\u00fcdemann HP et al (2003) Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol 13(6):1213\u20131223. https:\/\/doi.org\/10.1007\/s00330-002-1730-6","journal-title":"Eur Radiol"},{"issue":"10","key":"6865_CR26","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ejso.2004.07.024","volume":"30","author":"F Denis","year":"2004","unstructured":"Denis F, Desbiez-Bourcier AV, Chapiron C, Arbion F, Body G, Brunereau L (2004) Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol 30(10):1069\u20131076. https:\/\/doi.org\/10.1016\/j.ejso.2004.07.024","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"6865_CR27","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/bjc.2013.473","volume":"109","author":"ML Marinovich","year":"2013","unstructured":"Marinovich ML, Macaskill P, Irwig L, Sardanelli F, von Minckwitz G, Mamounas E et al (2013) Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy. Br J Cancer 109(6):1528\u20131536. https:\/\/doi.org\/10.1038\/bjc.2013.473","journal-title":"Br J Cancer"},{"issue":"5","key":"6865_CR28","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.3390\/curroncol28050298","volume":"28","author":"K Steinhof-Radwa\u0144ska","year":"2021","unstructured":"Steinhof-Radwa\u0144ska K, Gra\u017cy\u0144ska A, Lorek A, Gisterek I, Barczyk-Gutowska A, Bobola A et al (2021) Contrast-enhanced spectral mammography assessment of patients treated with neoadjuvant chemotherapy for breast cancer. Curr Oncol 28(5):3448\u20133462. https:\/\/doi.org\/10.3390\/curroncol28050298","journal-title":"Curr Oncol"},{"key":"6865_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2021.03.003","author":"D Son","year":"2021","unstructured":"Son D, Phillips J, Mehta TS, Mehta R, Brook A, Dialani VM (2021) Patient preferences regarding use of contrast-enhanced imaging for breast cancer screening. Acad Radiol. https:\/\/doi.org\/10.1016\/j.acra.2021.03.003","journal-title":"Acad Radiol"},{"key":"6865_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.clinimag.2020.09.003","volume":"69","author":"J Sogani","year":"2021","unstructured":"Sogani J, Mango VL, Keating D, Sung JS, Jochelson MS (2021) Contrast-enhanced mammography: past, present, and future. Clin Imaging 69:269\u2013279. https:\/\/doi.org\/10.1016\/j.clinimag.2020.09.003","journal-title":"Clin Imaging"},{"issue":"2","key":"6865_CR31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2214\/AJR.17.18749","volume":"210","author":"MF Covington","year":"2018","unstructured":"Covington MF, Pizzitola VJ, Lorans R, Pockaj BA, Northfelt DW, Appleton CM et al (2018) The future of contrast-enhanced mammography. AJR Am J Roentgenol 210(2):292\u2013300. https:\/\/doi.org\/10.2214\/AJR.17.18749","journal-title":"AJR Am J Roentgenol"},{"issue":"15","key":"6865_CR32","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796\u20131804. https:\/\/doi.org\/10.1200\/JCO.2011.38.8595","journal-title":"J Clin Oncol"},{"issue":"9","key":"6865_CR33","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/modpathol.2015.74","volume":"28","author":"E Provenzano","year":"2015","unstructured":"Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C et al (2015) Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol 28(9):1185\u20131201. https:\/\/doi.org\/10.1038\/modpathol.2015.74","journal-title":"Mod Pathol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-06865-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T23:59:02Z","timestamp":1679875142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-06865-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["6865"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-06865-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"7 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maxine S Jochelson has received an honorarium from GE for speaking, and an honorarium for speaking at the Lynn Sage Breast Cancer Symposium and at MD Anderson. Janice S Sung has received research grants from Hologic and GE. The remaining authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Memorial Sloan Kettering Cancer Center (IRB# 17\u2013045). Study start date: February 28, 2017. ClinicalTrials.gov Identifier: NCT03070340.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}